Clinical Trial Update: To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety, tolerability, and preliminary efficacy of HMI-115 in male and female participants with Androgenetic alopecia over a 24-week…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Androgenetic Alopecia

Drugs mentioned

• HMI-115

Snippet

Sponsor: Hope Medicine (Nanjing) Co., Ltd | Conditions: Androgenetic Alopecia | Phase 1 | Status: COMPLETED